David Zacks News Today

Rockville, Md.—The Association for Research in Vision and Ophthalmology (ARVO) Foundation congratulates David Zacks, MD, PhD — 2023 recipient of the Kreissi

No change in visual acuity, office-visit interval almost doubled during 6 months

Kathleen Barton, Brian Gaudet, and David Zacks recently participated in a panel at the annual Susan A. Cahoon Annual Ethics and Professionalism Seminar hosted by Kilpatrick Townsend....

Kilpatrick Townsend’s Brian Gaudet and Katie Barton and David Zacks of Zacks Resolution recently participated in a panel at the annual Susan A. Cahoon Annual Ethics and Professionalism...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on $46.9m in a Series B financing round. The round included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round include ONL Therapeutics management, InFocus Ca...

ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months December 22, 2020 07:00 ET | Source: ONL Therapeutics ONL Therapeutics Ann Arbor, Michigan, UNITED STATES ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSW...